<DOC>
	<DOCNO>NCT02452021</DOCNO>
	<brief_summary>This prospective observational study design observe toxicity efficacy PBS proton RT patient esophageal cancer undergo trimodality therapy . The investigator hypothesize PBS proton RT associate favorable adverse event profile quality life , similar disease control outcomes , relative historical comparison patient treat photon RT .</brief_summary>
	<brief_title>Pencil Beam Scanning Proton Radiotherapy Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Age ≥ 18 year . Histological confirmation adenocarcinoma squamous cell carcinoma esophagus ( mid , distal , GE junction ) Stage T1N13M0 T24N03M0 American Joint Commission Cancer ( AJCC ) 7th edition Tumor extend ≤ 5 cm gastric cardia , base EGD PET/CT ECOG Performance Status ( PS ) 02 ( Appendix I ) Surgical consultation confirm patient appropriate candidate esophagectomy Medical oncology consultation confirm patient appropriate candidate chemotherapy Planned receive standard care neoadjuvant CRT , consist PBS proton RT ( 50 Gy/25 fraction ) concurrent chemotherapy ( weekly carboplatin paclitaxel ) , follow surgical resection Ability complete questionnaire ( ) assistance . Provide inform write consent . Willing return enrol institution followup ( Active Monitoring Phase study ) . Note : During Active Monitoring Phase study ( i.e. , active treatment observation ) , participant must willing return consent institution followup . Willing sign consent onto Mayo Clinic Radiotherapy Patient Outcomes Registry Biobanking study , IRB number 15000136 Cervical upper esophageal tumor part tumor &lt; 24 cm incisor Prior chemotherapy RT esophageal cancer History RT thorax Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment adverse event . Immunocompromised patient patient know HIV positive currently receive antiretroviral therapy . NOTE : Patients know HIV positive , without clinical evidence immunocompromised state , eligible trial . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Receiving investigational agent would consider treatment primary neoplasm . Other active malignancy ≤ 1 year prior registration . EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix . NOTE : If history prior malignancy , must receive specific treatment cancer . History myocardial infarction ≤6 month , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>